Vitamin D and Clinical Phenotypes of Parkinson’s Disease
Objective: To explore the relationship of clinical phenotypes of Parkinson's disease (PD) with vitamin D levels in Veterans diagnosed with PD. Background: PD is a heterogeneous neurodegenerative…Istradefylline for daytime sleepiness and sleep disturbances in patients with Parkinson’s disease: an open-label, 3-month study
Objective: To evaluate the effect of istradefylline on daytime sleepiness and sleep disturbances as well as motor symptoms in patients with Parkinson’s disease (PD) in…Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase
Objective: To determine the dose of APL-130277 required by each patient with Parkinson’s Disease (PD) to turn from OFF to Full ON. This dose is…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study
Objective: To determine the safety of single treatments of APL-130277 in patients with Parkinson’s disease (PD). Background: Patients with Parkinson’s disease (PD) frequently develop problematic…Prognosis and end-of-life status after emergency admissions in patients with Parkinson disease: a Japanese single center retrospective study
Objective: To investigate the status after the emergency admissions and to determine the cause and location of death in patients with Parkinson disease (PD). Background:…The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
Objective: The levodopa tablet is prone to dissolve in acidic conditions. We investigated whether gastric acid suppressants (histamine-2 receptor antagonists or proton pump inhibitors) and…Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease(PD) from OFF to fully ON: Preliminary Results from a Phase III Study
Objective: To determine if baseline disease severity could be correlated to the effective dose of APL-130277 that was required to turn a patient with PD…Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)
Objective: To compare levodopa PK, derived from ND0612 (a proprietary liquid levodopa/carbidopa formulation designed for subcutaneous (SC) administration) with Levodopa/Carbidopa Intestinal Gel (LCIG). Background: While…Does the side of onset affect motor and non-motor symptoms in Parkinson’s disease?
Objective: To assess the association between motor and non-motor symptoms of Parkinson’s Disease (PD) and side of onset considering hand dominance. Background: PD motor symptoms…Effect of levodopa-carbidopa intestinal gel on dyskinesia: Design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients
Objective: To examine the effect of levodopa-carbidopa intestinal gel (LCIG, designated carbidopa-levodopa enteral suspension in the US) treatment relative to that of optimized medical treatment…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.